GSK leanest with R&D spend in big pharma – but gets bang for its buckGlaxoSmithKline’s CEO Emma Walmsley has made great play of her company’s new approach to R&D under the leadership Share XGSK leanest with R&D spend in big pharma – but gets bang for its buckhttps://pharmaphorum.com/news/gsk-is-meanest-with-rd-spend-in-big-pharma/
Chasing Mylan, Hikma tries again with rejected generic Advair in USUK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for Share XChasing Mylan, Hikma tries again with rejected generic Advair in UShttps://pharmaphorum.com/news/chasing-mylan-hikma-tries-again-with-rejected-generic-advair-in-us/
GSK must continue to improve R&D, says CEO WalmsleyIt’s been two and a half years since Emma Walmsley took over as CEO of GlaxoSmithKline, and at Share XGSK must continue to improve R&D, says CEO Walmsleyhttps://pharmaphorum.com/news/gsk-must-continue-to-improve-rd-says-ceo-walmsley/
Shingrix and Trelegy shield GSK from Advair falloutGlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs Share XShingrix and Trelegy shield GSK from Advair fallouthttps://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/
GSK’s TB vaccine makes a big step forward towards licensingGlaxoSmithKline has spent 20 years trying to develop an improved vaccine for tuberculosis, and new data for its Share XGSK’s TB vaccine makes a big step forward towards licensinghttps://pharmaphorum.com/news/gsks-tb-vaccine-makes-a-big-step-forward-towards-licensing/
GSK’s PARP drug Zejula approved in wider ovarian cancer populationThe FDA has approved GlaxoSmithKline’s Zejula (niraparib) in a wider ovarian cancer indication, the first time a PARP Share XGSK’s PARP drug Zejula approved in wider ovarian cancer populationhttps://pharmaphorum.com/news/gsks-parp-drug-zejula-approved-in-wider-ovarian-cancer-population/
GSK sells travel vaccines to Bavarian NordicGlaxoSmithKline (GSK) has sold off two travel vaccines to Bavarian Nordic, as the company shifts its focus away Share XGSK sells travel vaccines to Bavarian Nordichttps://pharmaphorum.com/news/gsk-sells-travel-vaccines-to-bavarian-nordic/
GSK’s Walmsley backs #MeTooPay gender pay campaignGlaxoSmithKline chief executive Emma Walmsley is among more than 100 prominent businesswomen in the UK who have launched Share XGSK’s Walmsley backs #MeTooPay gender pay campaignhttps://pharmaphorum.com/news/gsks-walmsley-backs-metoopay-gender-pay-campaign/
FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSKThe FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by Share XFDA rejection scuppers AZ’s hopes of a COPD triple clash with GSKhttps://pharmaphorum.com/news/fda-rejection-scuppers-azs-hopes-of-a-copd-triple-clash-with-gsk/
